Skip to content
2000
Volume 7, Issue 1
  • ISSN: 1573-4072
  • E-ISSN: 1875-6646

Abstract

CRLX101 (formerly IT-101) is a first-in-class nanopharmaceutical, currently in Phase 2a development, which has been developed by covalently conjugating camptothecin (CPT) to a linear, cyclodextrin-polyethylene glycol (CDPEG) co-polymer that self-assembles into nanoparticles. As a nanometer-scale drug carrier system, the cyclodextrin polymeric nanoparticle technology, referred to as “CDP”, has unique design features and capabilities. Specifically, CRLX101 preclinical and clinical data confirm that CDP can address not only solubility, formulation, toxicity, and pharmacokinetic challenges associated with administration of CPT, but more importantly, can impart unique biological properties that enhance CPT pharmacodynamics and efficacy.

Loading

Article metrics loading...

/content/journals/cbc/10.2174/157340711795163866
2011-03-01
2024-12-11
Loading full text...

Full text loading...

/content/journals/cbc/10.2174/157340711795163866
Loading

  • Article Type:
    Research Article
Keyword(s): camptothecin; Nanopharmaceutical; oncology; topoisomerase 1
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test